Physiological, psychological and behavioural effects of long-acting reversible contraception

Conditions

Depression ,Sexual Dysfunction, menstrual disturbances

Mandisa Singata‐Madliki, Theresa A Lawrie, Yusentha Balakrishna, Florence Carayon‐Lefebvre d’Hellencourt, G Justus Hofmeyr

Reproductive Health2021-09-296 citations

10.1186/s12978-021-01232-6

Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial

Mandisa Singata‐Madliki, Florence Carayon‐Lefebvre d’Hellencourt, Theresa A Lawrie, Yusentha Balakrishna, G Justus Hofmeyr

International Journal of Gynecology & Obstetrics2021-01-1516 citations

10.1002/ijgo.13594

Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial

Mandisa Singata‐Madliki, G Justus Hofmeyr, Florence Carayon-Lefebvre d’Hellencourt, Theresa A Lawrie

BMJ Open2017-11-014 citations

10.1136/bmjopen-2017-019205

Interventions

IM injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL)

Levonorgestrel (LNG) Implant

Copper IUD (Paragard-T 380A®, Duramed)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: be eligible for the study a woman must meet all of the following criteria: ¿ 18-35 years of age ¿ HIV-seronegative ¿ Wants to use effective contraception ¿ Is able and willing to provide written informed consent ¿ Agrees to be randomised to either DMPA, NET-En, or copper IUD ¿ Agrees to use assigned method for 18 months ¿ Agrees to follow all study requirements ¿ Intends to stay in the study area for the next 18 months, and willing and able to provide adequate locator information ¿ If recently pregnant, is at least 6 weeks post-partum ¿ Is sexually active (has had vaginal sex within the last 3 months) or was pregnant within the last 3 months ¿ Agrees not to participate in studies of drugs or vaccines or any other clinical research study while participating in this study.

Exclusion criteria

Exclusion criteria: ¿ Reported medical contraindications (WHO MEC Category 3 or 4) to copper IUDs, NET-En, or DMPA, including: o recent septic abortion o suspicious unexplained vaginal bleeding o breast, cervical, uterine, or ovarian cancer o high BP or heart disease, venous thromboembolism, stroke, or diabetes o liver disease or liver tumours o use of liver enzyme inducing medications (see appendix 9) ¿ Is found to have pelvic tuberculosis or uterine fibroids with distortion of the uterine cavity on pelvic exam ¿ Has untreated mucopurulent cervicitis on exam, untreated pelvic inflammatory disease (PID), or untreated known gonorrhoea or chlamydia ¿ Has used DMPA, Net-En, or an IUD in the last 6 months ¿ Is pregnant or intending to become pregnant in the next 18 months ¿ Has had a hysterectomy or sterilization ¿ Has previously participated in the study ¿ Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe or complicate data interpretation

Design outcomes

Primary

Measure	Time frame
1.Depression	—

Countries

South Africa

Contacts

Public ContactMandisa Singata-Madliki

Co-Director, ECRU

mandisa.singata@gmail.com+27 43 7092709

Outcome results

None listed